It can target transcriptional dysregulation in cancer [hsa05202], pathways in cancer [hsa05200], and cell cycle pathway[hsa04110] via silencing CCND2 (Cyclin-D2), CDKN1B (cyclin-dependent kinase inhibitor 1B), IGF1R (insulin like growth factor 1 receptor), SMC3 (structural maintenance of chromosomes 3), ESPL1 (extra spindle pole bodies like 1), ITGAV (integrin subunit alpha V), and BMP4 (bone morphogenetic protein 4). Here, IGF1R is linked to cancer.